<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;ff=20240903204742&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;ff=20240903204742&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 04 Sep 2024 00:47:43 +0000</lastbuilddate>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>The Case for Restoring Organelles to Treat Ischemic Cardiomyopathy: Is DEPP1 an Attractive Target?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226384/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 3;150(10):787-790. doi: 10.1161/CIRCULATIONAHA.124.070750. Epub 2024 Sep 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226384/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39226384</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070750>10.1161/CIRCULATIONAHA.124.070750</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226384</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Abhinav Diwan</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Case for Restoring Organelles to Treat Ischemic Cardiomyopathy: Is DEPP1 an Attractive Target?</dc:title>
<dc:identifier>pmid:39226384</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070750</dc:identifier>
</item>
<item>
<title>Response by Kosiborod et al to Letter Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226383/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 3;150(10):e226-e227. doi: 10.1161/CIRCULATIONAHA.124.069707. Epub 2024 Sep 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226383/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39226383</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069707>10.1161/CIRCULATIONAHA.124.069707</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226383</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Kosiborod et al to Letter Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial"</dc:title>
<dc:identifier>pmid:39226383</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069707</dc:identifier>
</item>
<item>
<title>Angiotensin-(1-9) Retro-Enantiomer Peptide With Cardioprotective Activity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226382/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 3;150(10):816-820. doi: 10.1161/CIRCULATIONAHA.122.061322. Epub 2024 Sep 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226382/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39226382</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061322>10.1161/CIRCULATIONAHA.122.061322</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226382</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yvo Flores</dc:creator>
<dc:creator>Gerald Zapata-Torres</dc:creator>
<dc:creator>Agustín Nuñez</dc:creator>
<dc:creator>Douglas J Matthies</dc:creator>
<dc:creator>Larissa Alemán</dc:creator>
<dc:creator>Carolina Hernández-Fuentes</dc:creator>
<dc:creator>Gina Sánchez</dc:creator>
<dc:creator>Eyleen Araya</dc:creator>
<dc:creator>Fanny Guzman</dc:creator>
<dc:creator>Zully Pedrozo</dc:creator>
<dc:creator>Salvador Guardiola</dc:creator>
<dc:creator>Mónica Varese</dc:creator>
<dc:creator>Ernest Giralt</dc:creator>
<dc:creator>Ivan Maslov</dc:creator>
<dc:creator>Mark Del Borgo</dc:creator>
<dc:creator>Robert E Widdop</dc:creator>
<dc:creator>Silvana Valdebenito</dc:creator>
<dc:creator>Eliseo A Eugenin</dc:creator>
<dc:creator>Mario Chiong</dc:creator>
<dc:creator>Joseph A Hill</dc:creator>
<dc:creator>María Paz Ocaranza</dc:creator>
<dc:creator>Marcelo J Kogan</dc:creator>
<dc:creator>Sergio Lavandero</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Angiotensin-(1-9) Retro-Enantiomer Peptide With Cardioprotective Activity</dc:title>
<dc:identifier>pmid:39226382</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.061322</dc:identifier>
</item>
<item>
<title>Comparison of American and European Guideline Recommendations for Diagnostic Workup and Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226381/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>Guidelines help to facilitate treatment decisions based on available evidence, and also to provide recommendations in areas of uncertainty. In this paper, we compare the recommendations for stroke workup and secondary prevention of ischemic stroke and transient ischemic attack of the American Heart Association (AHA)/American Stroke Association (ASA) with the European Stroke Organization (ESO) guidelines. The primary aim of this paper is to offer clinicians guidance by identifying areas where...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 3;150(10):806-815. doi: 10.1161/CIRCULATIONAHA.124.069651. Epub 2024 Sep 3.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Guidelines help to facilitate treatment decisions based on available evidence, and also to provide recommendations in areas of uncertainty. In this paper, we compare the recommendations for stroke workup and secondary prevention of ischemic stroke and transient ischemic attack of the American Heart Association (AHA)/American Stroke Association (ASA) with the European Stroke Organization (ESO) guidelines. The primary aim of this paper is to offer clinicians guidance by identifying areas where there is consensus and where consensus is lacking, in the absence or presence of high-level evidence. We compared AHA/ASA with the ESO guideline recommendations for 7 different topics related to diagnostic stroke workup and secondary prevention. We categorized the recommendations based on class and level of evidence to determine whether there were relevant differences in the ratings of evidence that the guidelines used for its recommendations. Finally, we summarized major topics of agreement and disagreement, while also prominent knowledge gaps were identified. In total, we found 63 ESO and 82 AHA/ASA recommendations, of which 38 were on the same subject. Most recommendations are largely similar, but not all are based on high-level evidence. For many recommendations, AHA/ASA and ESO assigned different levels of evidence. For the 10 recommendations with <i>Level A</i> evidence (high quality) in AHA/ASA, ESO only labeled 4 of these as <i>high quality</i>. There are many remaining issues with either no or insufficient evidence, and some topics that are not covered by both guidelines. Most ESO and AHA/ASA Guideline recommendations for stroke workup and secondary prevention were similar. However not all were based on high-level evidence and the appointed level of evidence often differed. Clinicians should not blindly follow all guideline recommendations; the accompanying level of evidence informs which recommendations are based on robust evidence. Topics with lower levels of evidence, or those with recommendations that disagree or are missing, may be an incentive for further clinical research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226381/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39226381</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069651>10.1161/CIRCULATIONAHA.124.069651</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226381</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Maxim J H L Mulder</dc:creator>
<dc:creator>Tim Y Cras</dc:creator>
<dc:creator>James Shay</dc:creator>
<dc:creator>Diederik W J Dippel</dc:creator>
<dc:creator>James F Burke</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Comparison of American and European Guideline Recommendations for Diagnostic Workup and Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack</dc:title>
<dc:identifier>pmid:39226381</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069651</dc:identifier>
</item>
<item>
<title>Letter by Weir Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226380/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 3;150(10):e224-e225. doi: 10.1161/CIRCULATIONAHA.123.067970. Epub 2024 Sep 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226380/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39226380</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067970>10.1161/CIRCULATIONAHA.123.067970</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226380</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Robin A P Weir</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Weir Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity"</dc:title>
<dc:identifier>pmid:39226380</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067970</dc:identifier>
</item>
<item>
<title>Using Behavioral Science to Improve Cardiovascular Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 3;150(10):743-745. doi: 10.1161/CIRCULATIONAHA.124.070103. Epub 2024 Sep 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39226379</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070103>10.1161/CIRCULATIONAHA.124.070103</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226379</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kevin G Volpp</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Using Behavioral Science to Improve Cardiovascular Health</dc:title>
<dc:identifier>pmid:39226379</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070103</dc:identifier>
</item>
<item>
<title>Monocytes Reprogrammed by 4-PBA Potently Contribute to the Resolution of Inflammation and Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39224974/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study describes a robust and effective approach to generate resolving monocytes, characterizes novel mechanisms for targeted monocyte reprogramming, and offers a precision therapeutics for atherosclerosis based on delivering reprogrammed resolving monocytes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 3. doi: 10.1161/CIRCRESAHA.124.325023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Chronic inflammation initiated by inflammatory monocytes underlies the pathogenesis of atherosclerosis. However, approaches that can effectively resolve chronic low-grade inflammation targeting monocytes are not readily available. The small chemical compound 4-phenylbutyric acid (4-PBA) exhibits broad anti-inflammatory effects in reducing atherosclerosis. Selective delivery of 4-PBA reprogrammed monocytes may hold novel potential in providing targeted and precision therapeutics for the treatment of atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Systems analyses integrating single-cell RNA sequencing and complementary immunologic approaches characterized key resolving characteristics as well as defining markers of reprogrammed monocytes trained by 4-PBA. Molecular mechanisms responsible for monocyte reprogramming were assessed by integrated biochemical and genetic approaches. The intercellular propagation of homeostasis resolution was evaluated by coculture assays with donor monocytes trained by 4-PBA and recipient naive monocytes. The in vivo effects of monocyte resolution and atherosclerosis prevention by 4-PBA were assessed with the high-fat diet-fed <i>ApoE</i><sup><i>-/-</i></sup> mouse model with IP 4-PBA administration. Furthermore, the selective efficacy of 4-PBA-trained monocytes was examined by IV transfusion of ex vivo trained monocytes by 4-PBA into recipient high-fat diet-fed <i>ApoE</i><sup><i>-/-</i></sup> mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In this study, we found that monocytes can be potently reprogrammed by 4-PBA into an immune-resolving state characterized by reduced adhesion and enhanced expression of anti-inflammatory mediator CD24. Mechanistically, 4-PBA reduced the expression of ICAM-1 (intercellular adhesion molecule 1) via reducing peroxisome stress and attenuating SYK (spleen tyrosine kinase)-mTOR (mammalian target of rapamycin) signaling. Concurrently, 4-PBA enhanced the expression of resolving mediator CD24 through promoting PPARγ (peroxisome proliferator-activated receptor γ) neddylation mediated by TOLLIP (toll-interacting protein). 4-PBA-trained monocytes can effectively propagate anti-inflammation activity to neighboring monocytes through CD24. Our data further demonstrated that 4-PBA-trained monocytes effectively reduce atherosclerosis pathogenesis when administered in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study describes a robust and effective approach to generate resolving monocytes, characterizes novel mechanisms for targeted monocyte reprogramming, and offers a precision therapeutics for atherosclerosis based on delivering reprogrammed resolving monocytes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39224974/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39224974</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325023>10.1161/CIRCRESAHA.124.325023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39224974</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Shuo Geng</dc:creator>
<dc:creator>Ran Lu</dc:creator>
<dc:creator>Yao Zhang</dc:creator>
<dc:creator>Yajun Wu</dc:creator>
<dc:creator>Ling Xie</dc:creator>
<dc:creator>Blake Caldwell</dc:creator>
<dc:creator>Kisha Pradhan</dc:creator>
<dc:creator>Ziyue Yi</dc:creator>
<dc:creator>Jacqueline Hou</dc:creator>
<dc:creator>Feng Xu</dc:creator>
<dc:creator>Xian Chen</dc:creator>
<dc:creator>Liwu Li</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Monocytes Reprogrammed by 4-PBA Potently Contribute to the Resolution of Inflammation and Atherosclerosis</dc:title>
<dc:identifier>pmid:39224974</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325023</dc:identifier>
</item>
<item>
<title>Management of Antiplatelet Therapy After Coronary Stenting in Patients Requiring Non-Cardiac Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39222897/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 22:S0735-1097(24)08251-2. doi: 10.1016/j.jacc.2024.08.039. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39222897/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39222897</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.039>10.1016/j.jacc.2024.08.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39222897</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Management of Antiplatelet Therapy After Coronary Stenting in Patients Requiring Non-Cardiac Surgery</dc:title>
<dc:identifier>pmid:39222897</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.039</dc:identifier>
</item>
<item>
<title>Impact of Renal &amp;amp; Liver Function on Clinical Outcomes Following Tricuspid Valve Transcatheter Edge-to-Edge Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39222896/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Baseline end-organ function were associated with HF hospitalization and death in patients with severe TR. At 12 months, eGFR and MELD-XI scores were not statistically significantly different between the overall TEER and Control groups. In patients who had successful TEER, statistically significant, yet small, favorable changes occurred for both eGFR and MELD-XI. Further investigation is needed to assess whether these changes in end-organ function after successful TEER are clinically...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 23:S0735-1097(24)08275-5. doi: 10.1016/j.jacc.2024.08.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: TRILUMINATE Pivotal is a prospective, randomized, controlled study of patients with severe tricuspid regurgitation (TR). Venous congestion due to TR may lead to end-organ dysfunction and failure. The potential to reverse or stop further deterioration in end-organ function is an important goal of treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: Examine changes in end-organ function after tricuspid transcatheter edge-to-edge repair (TEER) and assess the association of baseline end-organ function with heart failure (HF) hospitalizations and mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Subjects were randomized 1:1 to either the TEER group (TriClip™ System + medical therapy) or Control group (medical therapy alone). Laboratory assessments and TR grading were performed at baseline and at all follow-up visits (discharge, 30 days, 6 months, and 12 months). An independent echocardiography core laboratory assessed TR severity and an independent clinical events committee adjudicated adverse events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: 572 subjects were enrolled and randomized (285 TEER, 287 Control). Patients with moderate to severe end-organ impairment (eGFR &lt;45 ml/min/1.73m<sup>2</sup> or MELD-XI >;15) at baseline had increased incidence of HF hospitalization and death through 12 months, regardless of treatment. There were no statistically significant differences between TEER and Control in eGFR or MELD-XI at 12 months. In subgroup analyses examining only successful TEER patients (moderate or less TR at discharge) compared to control patients, as well as when censoring patients with normal baseline values, both eGFR (+3.55 ± 1.04 vs 0.07 ± 1.10 , p=0.022) and MELD-XI (-0.52 ± 0.18 vs 0.34 ± 0.18, p=0.0007) improved.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Baseline end-organ function were associated with HF hospitalization and death in patients with severe TR. At 12 months, eGFR and MELD-XI scores were not statistically significantly different between the overall TEER and Control groups. In patients who had successful TEER, statistically significant, yet small, favorable changes occurred for both eGFR and MELD-XI. Further investigation is needed to assess whether these changes in end-organ function after successful TEER are clinically meaningful and reduce HF hospitalization or death.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39222896/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39222896</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.044>10.1016/j.jacc.2024.08.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39222896</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ulrich P Jorde</dc:creator>
<dc:creator>Raymond Benza</dc:creator>
<dc:creator>Patrick M McCarthy</dc:creator>
<dc:creator>Gorav Ailawadi</dc:creator>
<dc:creator>Brian Whisenant</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Peter Tadros</dc:creator>
<dc:creator>Hursh Naik</dc:creator>
<dc:creator>Neil Fam</dc:creator>
<dc:creator>Andrew J Sauer</dc:creator>
<dc:creator>Sandhya Murthy</dc:creator>
<dc:creator>Saibal Kar</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Nadira Hamid</dc:creator>
<dc:creator>Jacob Zbinden</dc:creator>
<dc:creator>Paul Sorajja</dc:creator>
<dc:creator>David Adams</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Renal &amp;amp; Liver Function on Clinical Outcomes Following Tricuspid Valve Transcatheter Edge-to-Edge Repair</dc:title>
<dc:identifier>pmid:39222896</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.044</dc:identifier>
</item>
<item>
<title>Excess mortality and hospitalizations associated with seasonal influenza in patients with heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39222895/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our results indicate that influenza activity likely causes substantial morbidity and mortality among patients with heart failure. Notably, our study suggests that approximately 2.6% of all deaths and 5.0% of all hospitalizations with influenza or pneumonia may be attributed to influenza in patients with heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 28:S0735-1097(24)08311-6. doi: 10.1016/j.jacc.2024.08.048. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Influenza virus may cause severe infection in patients with heart failure. It is known that influenza infection is associated with increased morbidity and mortality in patients with heart failure. However, less is known about the excess burden of morbidity and mortality caused by influenza infection in patients with heart failure at a population level.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To estimate the excess burden of morbidity and mortality as determined by annual excess number of deaths and hospitalizations associated with influenza infection in patients with heart failure in Denmark.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We collected nationwide data on weekly number of deaths and hospitalizations among patients with heart failure in Denmark and weekly estimates of influenza circulation as determined by the proportion of positive influenza samples analyzed at all Danish Hospitals. These data were correlated in a time series linear regression model and this model was used to estimate the annual excess number of deaths and hospitalizations attributable to influenza circulation among patients with heart failure in Denmark. The model also included data on weekly mean temperature and restricted cubic spline terms to account for seasonality and trends over time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Data were available from 2010 to 2018 encompassing 8 influenza seasons with an annual mean of 25180 samples tested for influenza at Danish hospitals. Among an annual mean of 70570 patients with heart failure, our model estimated that influenza activity was associated with an annual excess of 250 all cause deaths (95%CI 144-489) corresponding to 2.6% of all all-cause deaths (95%CI 1.5% - 5.1%) in patients with heart failure. Similarly, influenza activity was associated with an annual excess of 115 cardiovascular deaths (95%CI 62-244) corresponding to 2.9% of all cardiovascular deaths (95%CI 1.5% - 6.1%). Influenza activity was also associated with an annual excess of 251 hospitalizations for pneumonia or influenza (95%CI 107-533) corresponding to 5.0% of all hospitalizations for pneumonia or influenza.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results indicate that influenza activity likely causes substantial morbidity and mortality among patients with heart failure. Notably, our study suggests that approximately 2.6% of all deaths and 5.0% of all hospitalizations with influenza or pneumonia may be attributed to influenza in patients with heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39222895/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39222895</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.048>10.1016/j.jacc.2024.08.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39222895</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel Modin</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Niklas Dyrby Johansen</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Ramona Trebbien</dc:creator>
<dc:creator>Thyra Grove Krause</dc:creator>
<dc:creator>Jens-Ulrik Stæhr Jensen</dc:creator>
<dc:creator>Mikkel Porsborg Andersen</dc:creator>
<dc:creator>Gunnar Gislason</dc:creator>
<dc:creator>Tor Biering-Sørensen</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Excess mortality and hospitalizations associated with seasonal influenza in patients with heart failure</dc:title>
<dc:identifier>pmid:39222895</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.048</dc:identifier>
</item>
<item>
<title>Treating Hypertension With a Single (Combination) Pill: Changing the Paradigm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39222894/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 22:S0735-1097(24)08253-6. doi: 10.1016/j.jacc.2024.08.041. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39222894/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39222894</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.041>10.1016/j.jacc.2024.08.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39222894</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Oyere K Onuma</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Treating Hypertension With a Single (Combination) Pill: Changing the Paradigm</dc:title>
<dc:identifier>pmid:39222894</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.041</dc:identifier>
</item>
<item>
<title>M-TEER for Functional MR: Erasing all doubt</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39222893/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 22:S0735-1097(24)08249-4. doi: 10.1016/j.jacc.2024.08.037. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39222893/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39222893</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.037>10.1016/j.jacc.2024.08.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39222893</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Penta Bhavanadhar</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>M-TEER for Functional MR: Erasing all doubt</dc:title>
<dc:identifier>pmid:39222893</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.037</dc:identifier>
</item>
<item>
<title>Flecainide to Prevent Atrial Arrhythmia after Patent Foramen Ovale Closure, the AFLOAT Study: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39222035/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the first 6 months following successful PFO closure, AA (≥30s) occurred in 28.5% of cases, mostly in the first month after the procedure. Flecainide did not prevent AA after PFO closure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 2. doi: 10.1161/CIRCULATIONAHA.124.071186. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The real incidence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this complication can be prevented remain unknown. This study assessed if flecainide is effective to prevent AA during the first 3 months after PFO closure, and if 6 months treatment by flecainide is more effective than 3 months to prevent AA after PFO closure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: AFLOAT is a prospective, multicentre, randomized, open-label, superiority trial with a blind evaluation of all the endpoints (PROBE design). Patients were randomized in a 1:1:1 ratio after PFO closure to receive flecainide (150 mg once a day in a sustained-release (SR) dose) for 3 months, flecainide (150 mg od SR dose) for 6 months, or no additional treatment (standard-of-care) for 6 months. The primary endpoint was the percentage of patients with at least one episode AA (≥30s) recorded within 3 months after PFO closure on long-term monitoring with an insertable cardiac monitor (ICM). The secondary endpoint was the percentage of patients with at least one episode of AA (≥30s) recorded with ICM during the 3-6 months period after PFO closure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: 186 patients were included (mean age 54 years, male 68.8%) and AA (≥30s) occurred in 53 (28.5%) patients during the 6-month follow-up; 86.8% of these AA events occurred in the first month after PFO closure. The primary outcome occurred in 33/123 (26.8%) and 16/63 (25.4%) patients receiving flecainide for at least 3 months or standard of care, respectively [Risk Difference (RD) 1.4%; 95% confidence interval (CI) -12.9% to 13.8%, NS]. The secondary endpoint occurred in 3/60 (5.0%), 4/63 (6.3%), and 5/63 (7.9%) patients receiving flecainide 6 months, 3 months or standard of care, respectively [RD -2.9%; 95% CI -12.7% to 6.9%, and RD -1.6%; 95% CI -11.8% to 8.6%, respectively].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the first 6 months following successful PFO closure, AA (≥30s) occurred in 28.5% of cases, mostly in the first month after the procedure. Flecainide did not prevent AA after PFO closure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39222035/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39222035</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071186>10.1161/CIRCULATIONAHA.124.071186</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39222035</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Marie Hauguel-Moreau</dc:creator>
<dc:creator>Paul Guedeney</dc:creator>
<dc:creator>Claire Dauphin</dc:creator>
<dc:creator>Vincent Auffret</dc:creator>
<dc:creator>Jen-Michel Clerc</dc:creator>
<dc:creator>Eloi Marijon</dc:creator>
<dc:creator>Meyer Elbaz</dc:creator>
<dc:creator>Philippe Aldebert</dc:creator>
<dc:creator>Farzin Beygui</dc:creator>
<dc:creator>Wissam Abi Khalil</dc:creator>
<dc:creator>Antoine Da Costa</dc:creator>
<dc:creator>Jean-Christophe Macia</dc:creator>
<dc:creator>Simon Elhadad</dc:creator>
<dc:creator>Guillaume Cayla</dc:creator>
<dc:creator>Xavier Iriart</dc:creator>
<dc:creator>Mikael Laredo</dc:creator>
<dc:creator>Thomas Rolland</dc:creator>
<dc:creator>Yassine Temmar</dc:creator>
<dc:creator>Maria Elisabeta Gheorghiu</dc:creator>
<dc:creator>Delphine Brugier</dc:creator>
<dc:creator>Johanne Silvain</dc:creator>
<dc:creator>Nadjib Hammoudi</dc:creator>
<dc:creator>Guillaume Duthoit</dc:creator>
<dc:creator>Abdourahmane Diallo</dc:creator>
<dc:creator>Eric Vicaut</dc:creator>
<dc:creator>Gilles Montalescot</dc:creator>
<dc:creator>ACTION Study Group</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Flecainide to Prevent Atrial Arrhythmia after Patent Foramen Ovale Closure, the AFLOAT Study: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39222035</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071186</dc:identifier>
</item>
<item>
<title>Rare Genetic Variants in &lt;em>;LDLR&lt;/em>;, &lt;em>;APOB&lt;/em>;, and &lt;em>;PCSK9&lt;/em>; are Associated with Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39222019/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>Background: Despite a proposed causal role for low-density lipoprotein cholesterol (LDL-C) in aortic stenosis (AS), randomized controlled trials of lipid-lowering therapy failed to prevent severe AS. We aimed to assess the impact on AS and peak velocity across the aortic valve conferred by lifelong alterations in LDL-C levels mediated by protein-disrupting variants in three clinically significant genes for LDL metabolism (LDLR, APOB, PCSK9). Methods: We utilized sequencing data and electronic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 2. doi: 10.1161/CIRCULATIONAHA.124.070982. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Despite a proposed causal role for low-density lipoprotein cholesterol (LDL-C) in aortic stenosis (AS), randomized controlled trials of lipid-lowering therapy failed to prevent severe AS. We aimed to assess the impact on AS and peak velocity across the aortic valve conferred by lifelong alterations in LDL-C levels mediated by protein-disrupting variants in three clinically significant genes for LDL metabolism (<i>LDLR</i>, <i>APOB</i>, <i>PCSK9</i>). <b>Methods:</b> We utilized sequencing data and electronic health records from UK Biobank (UKB) and All of Us and magnetic resonance imaging data from UKB. We identified predicted protein-disrupting variants with the LOFTEE and AlphaMissense algorithms and evaluated their associations with LDL-C and peak velocity across the aortic valve (UK Biobank), as well as diagnosed AS and aortic valve replacement (UK Biobank + All of Us). <b>Results:</b> We included 421,049 unrelated participants (5,621 with AS) in UKB and 195,519 unrelated participants (1,087 with AS) in All of Us. Carriers of protein-disrupting variants in <i>LDLR</i> had higher mean LDL-C (UKB: +42.6 mg/dl, P=4.4e-237) and greater risk of AS (meta-analysis: odds ratio [OR] =3.52 [95% CI 2.39-5.20], P=2.3e-10) and aortic valve replacement (meta-analysis: OR=3.78 [95% CI 2.26-6.32], P=4.0e-7). Carriers of protein-disrupting variants in <i>APOB</i> or <i>PCSK9</i> had lower mean LDL-C (UKB: -32.3 mg/dl, P&lt;5e-324) and lower risk of AS (meta-analysis: OR=0.49 [0.31-0.75], P=0.001) and aortic valve replacement (meta-analysis: OR=0.54 [0.30-0.97], P=0.04). Among 57,371 UKB imaging substudy participants, peak velocities across the aortic valve were greater in carriers of protein-disrupting variants in LDLR (+12.2cm/s, P=1.6e-5) and lower in carriers of protein-disrupting variants in <i>PCSK9</i> (-6.9cm/s, P=0.022). <b>Conclusions:</b> Rare genetic variants that confer lifelong higher or lower LDL-C levels are associated with substantially increased and decreased risk of AS, respectively. Early and sustained lipid-lowering therapy may slow or prevent AS development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39222019/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39222019</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070982>10.1161/CIRCULATIONAHA.124.070982</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39222019</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Joel Rämö</dc:creator>
<dc:creator>Sean J Jurgens</dc:creator>
<dc:creator>Shinwan Kany</dc:creator>
<dc:creator>Seung Hoan Choi</dc:creator>
<dc:creator>Xin Wang</dc:creator>
<dc:creator>Andrey N Smirnov</dc:creator>
<dc:creator>Sam Freesun Friedman</dc:creator>
<dc:creator>Mahnaz Maddah</dc:creator>
<dc:creator>Shaan Khurshid</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>James Paul Pirruccello</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Rare Genetic Variants in &lt;em>;LDLR&lt;/em>;, &lt;em>;APOB&lt;/em>;, and &lt;em>;PCSK9&lt;/em>; are Associated with Aortic Stenosis</dc:title>
<dc:identifier>pmid:39222019</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070982</dc:identifier>
</item>
<item>
<title>Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39222018/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with DDAF and vascular disease are at higher risk of stroke and cardiovascular events and may derive a greater benefit from anticoagulation than patients with DDAF without vascular disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 2:ehae596. doi: 10.1093/eurheartj/ehae596. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: These pre-specified analyses of the NOAH-AFNET 6 (n=2534 patients) and ARTESiA (n=4012 patients) trials compared anticoagulation to no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In patients with vascular disease (NOAH-AFNET 6 56%, ARTESiA 46.0%), stroke, myocardial infarction, systemic or pulmonary embolism, or cardiovascular death occurred at 3.9%/patient-year with and 5.0%/patient-year without anticoagulation (NOAH-AFNET 6), and 3.2%/patient-year with and 4.4%/patient-year without anticoagulation (ARTESiA). Without vascular disease, outcomes were equal with and without anticoagulation (NOAH-AFNET 6 2.7%/patient-year, ARTESiA 2.3%/patient-year in both randomised groups). Meta-analysis found consistent results across both trials (I2heterogeneity=6%) with a trend for interaction with randomised therapy (pinteraction=0.08). Stroke/SE behaved similarly. Anticoagulation increased major bleeding in vascular disease patients (edoxaban 2.1%/patient-year, no anticoagulation 1.3%/patient-year; apixaban 1.7%/patient-year; no anticoagulation 1.1%/patient-year; incidence rate ratio 1.55 [1.10-2.20]) and without vascular disease (edoxaban 2.2%/patient-year; no anticoagulation 0.6%/patient-year; apixaban 1.4%/patient-year; no anticoagulation 1.1%/patient-year, incidence rate ratio 1.93 [0.72-5.20]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with DDAF and vascular disease are at higher risk of stroke and cardiovascular events and may derive a greater benefit from anticoagulation than patients with DDAF without vascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39222018/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39222018</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae596>10.1093/eurheartj/ehae596</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39222018</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Renate B Schnabel</dc:creator>
<dc:creator>Juan Benezet-Mazuecos</dc:creator>
<dc:creator>Nina Becher</dc:creator>
<dc:creator>William F McIntyre</dc:creator>
<dc:creator>Alexander Fierenz</dc:creator>
<dc:creator>Shun Fu Lee</dc:creator>
<dc:creator>Andreas Goette</dc:creator>
<dc:creator>Dan Atar</dc:creator>
<dc:creator>Emanuele Bertaglia</dc:creator>
<dc:creator>Alexander P Benz</dc:creator>
<dc:creator>Gregory Chlouverakis</dc:creator>
<dc:creator>David H Birnie</dc:creator>
<dc:creator>Wolfgang Dichtl</dc:creator>
<dc:creator>Carina Blomstrom-Lundqvist</dc:creator>
<dc:creator>A John Camm</dc:creator>
<dc:creator>Julia W Erath</dc:creator>
<dc:creator>Emmanuel Simantirakis</dc:creator>
<dc:creator>Valentina Kutyifa</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Philippe Mabo</dc:creator>
<dc:creator>Eloi Marijon</dc:creator>
<dc:creator>Lena Rivard</dc:creator>
<dc:creator>Ulrich Schotten</dc:creator>
<dc:creator>Marco Alings</dc:creator>
<dc:creator>Susanne Sehner</dc:creator>
<dc:creator>Tobias Toennis</dc:creator>
<dc:creator>Cecilia Linde</dc:creator>
<dc:creator>Panos Vardas</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Antonia Zapf</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Jeff S Healey</dc:creator>
<dc:creator>Paulus Kirchhof</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials</dc:title>
<dc:identifier>pmid:39222018</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae596</dc:identifier>
</item>
<item>
<title>Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39221911/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among women with PPCM, bromocriptine treatment in addition to standard of care was associated with better maternal outcomes after 6 months.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 2:ehae559. doi: 10.1093/eurheartj/ehae559. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Peripartum cardiomyopathy (PPCM) remains a serious threat to maternal health around the world. While bromocriptine, in addition to standard treatment for heart failure, presents a promising pathophysiology-based disease-specific treatment option in PPCM, the evidence regarding its efficacy remains limited. This study aimed to determine whether bromocriptine treatment is associated with improved maternal outcomes in PPCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PPCM patients from the EORP PPCM registry with available follow-up were included. The main exposure of this exploratory non-randomized analysis was bromocriptine treatment, and the main outcome was a composite endpoint of maternal outcome (death or hospital readmission within the first 6 months after diagnosis, or persistent severe left ventricular dysfunction [left ventricular ejection fraction &lt;35%] at 6-month follow-up). Inverse probability weighting was used to minimize the effects of confounding by indication. Multiple imputation was used to account for missing data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 552 patients with PPCM, 85 were treated with bromocriptine (15%). The primary endpoint was available in 491 patients (89%) and occurred in 18 out of 82 patients treated with bromocriptine in addition to standard of care (22%) and in 136 out of 409 patients treated with standard of care (33%) (p=0.044). In complete case analysis, bromocriptine treatment was associated with reduced adverse maternal outcome (odds ratio [OR] 0.29, 95% confidence interval [CI] 0.10-0.83, p=0.021). This association remained after applying multiple imputation and methods to correct for confounding by indication (inverse probability weighted model on imputed data OR 0.39, 95% CI 0.19-0.81, p=0.011). Thrombo-embolic events were observed in 5.9% of the patients in the bromocriptine group versus 5.6% in the standard of care group (p=0.900).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among women with PPCM, bromocriptine treatment in addition to standard of care was associated with better maternal outcomes after 6 months.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39221911/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39221911</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae559>10.1093/eurheartj/ehae559</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39221911</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Bart van Essen</dc:creator>
<dc:creator>Charle Viljoen</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Alice Jackson</dc:creator>
<dc:creator>Denise Hilfiker-Kleiner</dc:creator>
<dc:creator>Julian Hoevelmann</dc:creator>
<dc:creator>Alexandre Mebazaa</dc:creator>
<dc:creator>Hasan Ali Farhan</dc:creator>
<dc:creator>Sorel Goland</dc:creator>
<dc:creator>Wouter Ouwerkerk</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Petar M Seferović</dc:creator>
<dc:creator>Jasper Tromp</dc:creator>
<dc:creator>Karen Sliwa</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry</dc:title>
<dc:identifier>pmid:39221911</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae559</dc:identifier>
</item>
<item>
<title>From a club of friends to an institution: past successes and future challenges for the European Society of Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39221816/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 2:ehae505. doi: 10.1093/eurheartj/ehae505. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39221816/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39221816</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae505>10.1093/eurheartj/ehae505</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39221816</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>From a club of friends to an institution: past successes and future challenges for the European Society of Cardiology</dc:title>
<dc:identifier>pmid:39221816</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae505</dc:identifier>
</item>
<item>
<title>Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39221651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this population, treatment with CSL112 compared to placebo was associated with a significantly lower risk of recurrent cardiovascular events among patients with a baseline LDL-C ≥100 mg/dL. Further studies need to confirm that CSL112 efficacy is influenced by baseline LDL-C.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 2:ehae614. doi: 10.1093/eurheartj/ehae614. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce the risk of the primary endpoint through 90 days versus placebo after acute myocardial infarction (MI). Nevertheless, given the well-established relationship between higher low-density lipoprotein cholesterol (LDL-C) and plaque burden, as well as greater risk reductions seen with PCSK9 inhibitors in patients with baseline LDL-C ≥100 mg/dL on statin therapy, the efficacy of CSL112 may be influenced by baseline LDL-C.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Overall, 18,219 patients with acute MI, multivessel coronary artery disease, and additional risk factors were randomized to either four weekly infusions of 6 g CSL112 or placebo. This exploratory post-hoc analysis evaluated cardiovascular outcomes by baseline LDL-C in patients prescribed guideline-directed statin therapy at the time of randomization (n=15,731).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: As baseline LDL-C increased, risk of the primary endpoint at 90 days lowered in those treated with CSL112 compared with placebo. In patients with LDL-C ≥100 mg/dL at randomization, there was a significant risk reduction of cardiovascular death, MI, or stroke in the CSL112 vs. placebo group at 90, 180, and 365 days (hazard ratio 0.69 [0.53-0.90], 0.71 [0.57-0.88], and 0.78 [0.65-0.93]). In contrast, there was no difference between treatment groups among those with LDL-C &lt;100 mg/dL at baseline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this population, treatment with CSL112 compared to placebo was associated with a significantly lower risk of recurrent cardiovascular events among patients with a baseline LDL-C ≥100 mg/dL. Further studies need to confirm that CSL112 efficacy is influenced by baseline LDL-C.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39221651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39221651</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae614>10.1093/eurheartj/ehae614</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39221651</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>Danielle Duffy</dc:creator>
<dc:creator>M Cecilia Bahit</dc:creator>
<dc:creator>Gerald Chi</dc:creator>
<dc:creator>Harvey White</dc:creator>
<dc:creator>Serge Korjian</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>A Michael Lincoff</dc:creator>
<dc:creator>Mark Heise</dc:creator>
<dc:creator>Bronwyn A Kingwell</dc:creator>
<dc:creator>Jose C Nicolau</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Jan H Cornel</dc:creator>
<dc:creator>Basil S Lewis</dc:creator>
<dc:creator>Dragos Vinereanu</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Christoph Bode</dc:creator>
<dc:creator>Ph Gabriel Steg</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Frank M Sacks</dc:creator>
<dc:creator>Kevin R Bainey</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>Philip Aylward</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>AEGIS-II Committees and Investigators</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial</dc:title>
<dc:identifier>pmid:39221651</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae614</dc:identifier>
</item>
<item>
<title>Restrictive or Liberal Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: 6-Month Mortality in the MINT Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39221566/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 2. doi: 10.1161/CIRCULATIONAHA.124.069917. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39221566/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39221566</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069917>10.1161/CIRCULATIONAHA.124.069917</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39221566</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Tabassome Simon</dc:creator>
<dc:creator>Brandon M Herbert</dc:creator>
<dc:creator>Maria Mori Brooks</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Shahab Ghafghazi</dc:creator>
<dc:creator>Claire Bouleti</dc:creator>
<dc:creator>Howard A Cooper</dc:creator>
<dc:creator>Eric L McCamant</dc:creator>
<dc:creator>Kevin R Bainey</dc:creator>
<dc:creator>Herbert D Aronow</dc:creator>
<dc:creator>J Dawn Abbott</dc:creator>
<dc:creator>Caroline Alsweiler</dc:creator>
<dc:creator>Marnie Bertolet</dc:creator>
<dc:creator>Dean A Fergusson</dc:creator>
<dc:creator>Andrew M Goldsweig</dc:creator>
<dc:creator>Paul C Hébert</dc:creator>
<dc:creator>Jeffrey L Carson</dc:creator>
<dc:creator>MINT Trial Investigators</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Restrictive or Liberal Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: 6-Month Mortality in the MINT Trial</dc:title>
<dc:identifier>pmid:39221566</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069917</dc:identifier>
</item>
<item>
<title>What We Have Learned About Reducing Low-Density Lipoprotein Cholesterol and Coronary Plaques</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39221517/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 2. doi: 10.1001/jamacardio.2024.3213. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39221517/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39221517</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3213>10.1001/jamacardio.2024.3213</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39221517</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Steven E Nissen</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>What We Have Learned About Reducing Low-Density Lipoprotein Cholesterol and Coronary Plaques</dc:title>
<dc:identifier>pmid:39221517</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3213</dc:identifier>
</item>
<item>
<title>Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39221516/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240903204742&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: At the lesion level, very intensive lipid-lowering therapy induced substantially greater PAV regression than described in previous vessel-level analyses. Compared with statin therapy alone, alirocumab treatment was associated with greater enlargement of the lesion MLA and more frequent transition of presumably high-risk plaque phenotypes into more stable, less lipid-rich plaque phenotypes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 2. doi: 10.1001/jamacardio.2024.3200. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Previous studies investigated atherosclerotic changes induced by lipid-lowering therapy in extensive coronary segments irrespective of baseline disease burden (a vessel-level approach).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the effects of lipid-lowering therapy on coronary lesions with advanced atherosclerotic plaque features and presumably higher risk for future events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The PACMAN-AMI randomized clinical trial (enrollment: May 2017 to October 2020; final follow-up: October 2021) randomized patients with acute myocardial infarction to receive alirocumab or placebo in addition to high-intensity statin therapy. In this post hoc lesion-level analysis, nonculprit lesions were identified as segments with plaque burden 40% or greater defined by intravascular ultrasound (IVUS). IVUS, near-infrared spectroscopy, and optical coherence tomography images at baseline and the 52-week follow-up were manually matched by readers blinded to treatment allocation. Data for this study were analyzed from October 2022 to November 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Alirocumab or placebo in addition to high-intensity statin therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Lesion-level imaging outcome measures, including high-risk plaque characteristics and phenotypes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 245 patients in whom lesions were found, 118 were in the alirocumab group (mean [SD] age, 58.2 [10.0] years; 101 [85.6%] male and 17 [14.4%] female) and 127 in the placebo group (mean [SD] age, 57.7 [8.8] years; 104 [81.9%] male and 23 [18.1%] female). Overall, 591 lesions were included: 287 lesions (118 patients, 214 vessels) in the alirocumab group and 304 lesions (127 patients, 239 vessels) in the placebo group. Lesion-level mean change in percent atheroma volume (PAV) was -4.86% with alirocumab vs -2.78% with placebo (difference, -2.02; 95% CI, -3.00 to -1.05; P &lt; .001). At the minimum lumen area (MLA) site, mean change in PAV was -10.14% with alirocumab vs -6.70% with placebo (difference, -3.36; 95% CI, -4.98 to -1.75; P &lt; .001). MLA increased by 0.15 mm2 with alirocumab and decreased by 0.07 mm2 with placebo (difference, 0.21; 95% CI, 0.01 to 0.41; P = .04). Among 122 lipid-rich lesions, 34 of 55 (61.8%) in the alirocumab arm and 27 of 67 (41.8%) in the placebo arm showed a less lipid-rich plaque phenotype at follow-up (P = .03). Among 63 lesions with thin-cap fibroatheroma at baseline, 8 of 26 (30.8%) in the alirocumab arm and 3 of 37 (8.1%) in the placebo arm showed a fibrous/fibrocalcific plaque phenotype at follow-up (P = .02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: At the lesion level, very intensive lipid-lowering therapy induced substantially greater PAV regression than described in previous vessel-level analyses. Compared with statin therapy alone, alirocumab treatment was associated with greater enlargement of the lesion MLA and more frequent transition of presumably high-risk plaque phenotypes into more stable, less lipid-rich plaque phenotypes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03067844.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39221516/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240903204742&v=2.18.0.post9+e462414">39221516</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3200>10.1001/jamacardio.2024.3200</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39221516</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Flavio G Biccirè</dc:creator>
<dc:creator>Ryota Kakizaki</dc:creator>
<dc:creator>Konstantinos C Koskinas</dc:creator>
<dc:creator>Yasushi Ueki</dc:creator>
<dc:creator>Jonas Häner</dc:creator>
<dc:creator>Hiroki Shibutani</dc:creator>
<dc:creator>Jacob Lønborg</dc:creator>
<dc:creator>Ernest Spitzer</dc:creator>
<dc:creator>Juan F Iglesias</dc:creator>
<dc:creator>Tatsuhiko Otsuka</dc:creator>
<dc:creator>George C M Siontis</dc:creator>
<dc:creator>Stefan Stortecky</dc:creator>
<dc:creator>Christoph Kaiser</dc:creator>
<dc:creator>Maria Ambühl</dc:creator>
<dc:creator>Laura Morf</dc:creator>
<dc:creator>Anna S Ondracek</dc:creator>
<dc:creator>Robert-Jan van Geuns</dc:creator>
<dc:creator>David Spirk</dc:creator>
<dc:creator>Joost Daemen</dc:creator>
<dc:creator>François Mach</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Thomas Engstrøm</dc:creator>
<dc:creator>Irene Lang</dc:creator>
<dc:creator>Sylvain Losdat</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial</dc:title>
<dc:identifier>pmid:39221516</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3200</dc:identifier>
</item>





























</channel>
</rss>